Risks and Benefits of Long-Term Treatment Long-termTreatment_… · Z6 n= 613 609 608 600 524 450...
Transcript of Risks and Benefits of Long-Term Treatment Long-termTreatment_… · Z6 n= 613 609 608 600 524 450...
23/06/2015
1
Risks and Benefits of Long-Term Treatment
Richard Eastell, MD, FRCP, FRCPath, FMedSciProfessor of Bone Metabolism University of Sheffield, Sheffield, UK
12th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care23rd July 2015
E-mail [email protected]
Sheffield, EnglandMore trees per capita than any city in Europe!
23/06/2015
2
Conflicts of Interest
• Research funding, consulting and honoraria fromo Novartis
o Amgen
o AstraZeneca
o Pfizer
o Warner Chilcott
o Sanofi
Overview of Osteoporosis Treatments: Long-term Efficacy Data
23/06/2015
3
Osteoporosis Treatment Extension Studies
0 2 4 6 8 10
Risedronate
Alendronate
Zoledronic acid
ALN = alendronate; DB = double-blind; EXT 1= extension 1; EXT 2= extension 2; FIT = Fracture Intervention Trial; FLEX = FIT Long-term EXtension; HORIZON-PFT = Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly Pivotal Fracture Trial; OL, Open-label; PBO = placebo; RCT = randomized controlled trial; RIS = risedronate; VERT-MN = Vertebral Efficacy with Risedronate Therapy MultiNational; Z3P3 = zoledronic acidtreatment for 3 years followed by placebo for 3 years; Z6 = zoledronic acid treatment for 6 years; ZOL = zoledronic acid. 1. Black DM, et al. N Engl J Med. 2007;356:1809-1822. 2. Black DM, et al. J Bone Miner Res. 2012; 27:243-254. 3. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis:A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT).Presented at ASBMR 2013 (abstract no. SA0389). 4. Black DM, et al. Lancet. 1996;348:1535-1541. 5. Cummings SR, et al. JAMA. 1998;280:2077–2082. 6. Black DM, et al. JAMA. 2006;296:2927-2938. 7. Reginster J-Y, et al. Osteoporos Int. 2000;11:83–91. 8. Sorensen OH, et al. Bone. 2003;32:120-126. 9. Mellström DD, et al. Calif Tissue Int. 2004;75:462-468.
Time (Years)
FIT4,5
ALN (n = 3236) PBO (n = 3223)
RCT – FLEX6
ALN 5 mg (n = 329) or 10 mg (n = 333) PBO (n = 437)
HORIZON-PFT1
ZOL (n = 3889) PBO (n = 3876)
RCT – EXT12
Z6 (n = 616)Z3P3 (n = 617)
VERT-MN7
RIS 2.5 mg (n = 408) 5 mg (n = 407) PBO (n = 407)
RCT – EXT8
RIS (n=135)PBO (n=130)
OL-EXT9RIS 7 yrs (n = 83)PBO 5 yrs/RIS 2yrs (n = 81)
RCT – EXT23
Z9 (n = 95)Z6P3 (n = 95)
Z6 n= 613 609 608 600 524 450
Z3P3 n= 615 613 606 602 540 467
Effect of Zoledronic Acid on Total Hip BMD over 6 Years: HORIZON PFTEffect of Zoledronic Acid on Total Hip BMD over 6 Years: HORIZON PFT
Time (Years From Core Study Baseline)
Subset of Core Study Population
Z6 Z3P3
0
Core + Extension study
–2.0–1.00.01.02.03.04.0
–3.0
5.0
Start of extension trial
1.4%
3 61 2 4 5
(0.58, 2.15)P = 0.0007**
5.06%*
+4.5%
+3.1%
Black DM, et al. JBMR 2012 Feb;27(2):243-54. *p < 0.0001, p value computed from 3-way ANOVA with treatment, stratum and region as explanatory variables**p value computed from 2-way ANOVA with treatment and region as explanatory variables
23/06/2015
4
Effect of Zoledronic Acid on Total Hip BMD over 9 Years: HORIZON PFT
MITT = Modified-intent-to-treat; ITT = Intent-to-treat; BMD = Bone mineral density; Bracketed value is P value, ZOL vs. placebo
0
1
2
3
4
5
6
7
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9
Ch
ang
e fr
om b
asel
ine
(%)
Time (years)
Z9
Z6P3
[0.069] [0.351]
Core Extension-1 Extension-2
Total hip BMD from Core StudyBaseline to Year 9 (ITT)
Parallel results for other BMD sites
-2
-1.5
-1
-0.5
0
Z9 Z6P3
Per
cen
tag
e ch
ang
e (%
)
Year 9 relative to Year 6 (MITT)
P = 0.183
Black DM...Eastell R. J Bone Miner Res. 2015 May;30(5):934-44
0
2
4
6
8
10
12
% P
atie
nts
ZOL PBO Z6 Z3P3 Z9 Z6P3
1010.9%%[310/2853]
3.3%[92/2822]
3.0%[14/469]
6.2%[30/486] 5.3%
[5/95]3.2%[3/95]
Morphometric vertebral fractures
Core Extension-1 Extension-2
Incidence of new Vertebral Morphometric Fractures in the core study, Years 3-6 and Years 6-9 (ITT)
70%*(62, 76) 49%†
(26, 95)
*P < 0.001 vs. placebo†P = 0.035 vs. Z3P3
40% (-144, 85)
p = 0.461
Black DM...Eastell R. J Bone Miner Res. 2015 May;30(5):934-44
23/06/2015
5
* Measured in clinical fracture arm only, ALN = alendronate, BMD = bone mineral density, FIT = Fracture Intervention Trial, FLEX = FIT Long-term Extension, FN = femoral neck, LS = lumbar spine. Black DM, et al. JAMA. 2006;296:2927–2938.
Effect of Alendronate on Femoral Neck BMD over 10 Years: FIT and FLEXEffect of Alendronate on Femoral Neck BMD over 10 Years: FIT and FLEX
ALN = alendronate, BMD = bone mineral density, FIT = Fracture Intervention Trial, FLEX = FIT Long-term Extension, LS = lumbar spineBlack DM, et al. JAMA. 2006;296:2927–2938.
Placebo 437 428 429 421 417 414Alendronate 662 659 657 654 650 646
No. at Risk
0
5
10
15
20
0 1 2 3 4 5 6
Time to First Fracture, Years
Cu
mu
lati
veIn
cid
ence
(%
)
RR, 0.45 (95% CI, 0.24–0.86)
Incidence of new Clinical Vertebral Fractures during FLEX
Alendronate (Pooled)Placebo
FIT
FLEX
All patients received ALN
23/06/2015
6
ALN = alendronate, BMD = bone mineral density, FIT = Fracture Intervention Trial, FLEX = FIT Long-term Extension, LS = lumbar spineBlack DM, et al. JAMA. 2006;296:2927–2938.
Incidence of new Non-vertebral Fractures during FLEX
Placebo 437 421 410 396 373 355Alendronate 662 642 619 585 565 537
No. at Risk
360
5
10
15
20
0 12 24 48 60 72
Time to First Fracture, months
Cu
mu
lati
veIn
cid
ence
(%
)
RR, 1.00 (95% CI, 0.76–1.32)
Alendronate (Pooled)Placebo
FIT
FLEX
All patients received ALN
RISEDRONATE: LS BMD Increased Over 7-Year Treatment Period1
BLN 1 2 3 5 6 7
Mea
n C
han
ge
in L
S B
MD
(%
)
4
-1
2
8
10
13
10
345
76
9
1112
*#
**
*
Ris 7 yrs (n=83)
Placebo 5 yrs
Ris 2 yrs (n=81)
Years
*#
*#*#
*#
*#
*#
* P<0.05 vs. baseline, # P<0.05 vs. placebo; BLN = baseline, Ris = risedronate1. Mellström DD, et al. Calcif Tissue Int. 2004;75:462–468.
23/06/2015
7
Continuous Risedronate: Antifracture Efficacy for Radiographic Vertebral Fractures Sustained Over 7 Years1
An
nu
aliz
ed I
nci
den
ce o
f N
ew V
erte
bra
l Fr
actu
res
1. Mellström DD, et al. Calcif Tissue Int. 2004;75:462–468.
Placebo 407 130 81Risedronate 407 130 83
7.6%
4.7%5.2%
3.8%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
Years 0-3 Years 4-5 Years 6-7
Placebo 5mg risedronate
Patients switched to risedronate 5 mg at start of year 6
12.3%
Bisphosphonates Reduce Fracture Risk
Khosla S, et al. J Clin Endocrinol Metab. 97: 2272–2282, 2012
23/06/2015
8
Safety and Long-Term Treatment with Bisphosphonates
Amino-bisphosphonates for Osteoporosis
• Widely used
o In 2008, four million women prescribed oral bisphosphonates in USA
• Safety evaluation for license based on clinical trials
o Only 50,000 treated for up to 3 years
• Thus, in long-term use, when these drugs are used in many more people with co-existents diseases, rare adverse events might become apparent
23/06/2015
9
Safety and Long-Term Treatment with Bisphosphonates - Outline
• Benefits of Bisphosphonates
• Safety issues
o Atypical femur fracture
o Osteonecrosis of the jaw
o Atrial fibrillation
o Oesophageal cancer
o Others
−Oesophagitis
−Chronic kidney disease
− Iritis
• Minimising safety concerns
• Recent references
o Khosla S, et al. J Clin Endocrinol Metab 97: 2272–2282, 2012
o McClung M, et al. Am J Med. 2013 Jan;126(1):13-20.
Atypical femur fracture
23/06/2015
10
What is an atypical fracture of the femur?
• Fracture of the subtrochanteric region or femoral shaft
• Transverse of short oblique orientation
• Minimal trauma
• Medial spike
• No comminution
Shane E, et al. J Bone Miner Res. 2014;29(1):1-23Neviaser AS, et al. J Orthop Trauma. 2008 May-Jun;22(5):346-50.
Atypical femur fractures
• There is prodromal pain in 75% of cases
• The fracture is bilateral in 25-50% of cases
• There is delayed healing in 25% of cases
• More likely if
o Use of glucocorticoids
o Use of proton pump inhibitors
• In series with radiographs
o Atypical fractures in about 10% of all subtrochanteric fractures
o These are more likely with increased duration of treatment
DM Black has estimated that for every 1000 hip fractures, we might expect 5 atypical fractures
23/06/2015
11
Meta-analysis of atypical femur fracture studies - 2
Gedmintas L, et al. J Bone Miner Res. 2013;28(8):1729-37.
Atypical femur fractures against time on treatment (years)
Dell R, et al. J Bone Miner Res. 2012; 27(12),2544–50
23/06/2015
12
Osteonecrosis of the jaw
Osteonecrosis of the jaw - case definitionfrom several societies (AAOMS, ASBMR, ESCEO)
• Exposed bone in the mouth
• Unhealed for >8 weeks
• No history of radiation therapy to the craniofacial region
Khan AA, et al. J Bone Miner Res. 2015 Jan;30(1):3-23
23/06/2015
13
Reported incidence estimates of osteonecrosis of the jaw coincident with the use of bisphosphonates (1,2)
Malignant conditions
Nonmalignant conditions
IV1 to 10 per 100
patientsRate not published
PO Rate not published1/1,000 to
1/300,000 patient-treatment years
1. Khosla S, et al. J Clin Endocrinol Metab. 97: 2272–2282, 2012, 2. Lee SH, et al. Osteoporos Int 2014 Mar;25(3):1131-9
Meta-analysis of12 studies of osteoporosis:OR=2.91 (95 % CI 1.62–5.22)
Risk factors for ONJ
• Dental surgery
o Extraction
• Intravenous bisphosphonates for oncology indication
o 97% of all cases
• Drugs
o Glucocorticoids
o Chemotherapy
• Co-existent diseases
o Diabetes mellitus
o Alcohol excess
23/06/2015
14
Atrial fibrillation
Atrial FibrillationMeta-analysis of trials
Relative risk with intravenous bisphosphonates is 1.4
Relative risk with Oral bisphosphonates is 1.2
Sharma A, et al. Am J Cardiol. 2014 Jun 1;113(11):1815-21
23/06/2015
15
Oesophageal cancer
FDA Letter to the Journal
• The US Food and Drug Administration recently reported 23 cases of esophageal cancer (between 1995 and 2008) in patients using the bisphosphonate alendronate
o and a further 31 cases in patients using bisphosphonates in Europe and Japan
• This could indicate increased risk of malignancy associated with bisphosphonate use
Wysowski DK. N Engl J Med. 2009;360(1):89–90.
23/06/2015
16
Meta-analysis of oesophageal cancer and oral bisphosphonates
Sun K, et al. Osteoporos Int. 2013;24:279–286
Closing Thoughts
23/06/2015
17
Adverse Publicity: Effect on Oral Bisphosphonate Use in USA
Wysowski DK, Greene P. Bone. 2013;57:423-428
Summary of benefits vs. risks for bisphosphonate treatment as a function of time
BenefitsHip, non-vertebral and spine reductions
Risks
Treatment 3-4 years
Benefits:Only spine reductions
Risks
Treatment Beyond 3-4 yrs
Benefitsunproven
Risks uncertain
Treatment Beyond 6 yrs with ZOL or 10
years with ALN
23/06/2015
18
Thanks to Dennis Black for Discussions
Which patients should be continued on treatment?
• Primary benefit is in reduction of vertebral fractures
• Therefore, logical to continue those at highest risk of vertebral fractures
• Continue treatment in those with highest risk of vertebral fractureo Strongest risk factors in treatment naïve patients are BMD and existing vertebral
fractures (also age)
23/06/2015
19
37
FLEX vertebral fracture benefit:
Who to continue?
Femoral Neck BMD T-Score (start FLEX)
5 Yr risk (%) Clinical Vert. Fx. In PBO
Number Needed to
Treat
All women in study
All BMD values 5.5 34
≤ -2.5 9.3 21
-2.5 to -2 5.8 33
≥ -2 2.3 81
No prevalent vert. fracture (start of FLEX)
≤ -2.5 8.0 24
-2.5 to -2 3.0 63
≥ -2 1.8 102
Prevalent vertebral fracture (start of FLEX)
≤ -2.5 11.1 17
-2.5 to -2 11.1 17
≥ -2 3.7 51Black, et al. NEJM. 2012 May 31;366(22):2051-3
Continue ZOL after 3 years?Summary
- Many women can be discontinued after 3 years of ZOL
- Those at highest risk for vertebral fracture will most likely benefit from continuation- Hip BMD T-score below -2.5
- Existing vertebral fracture (after initial therapy)
- A fracture during initial therapy
- After 6 years, almost all women can take a drug holiday for at least 3 years
Cosman F...Eastell R, Black DM. J Clin Endocrinol Metab. 2014 Dec;99(12):4546-54